Editas Medicine (EDIT) Misses Q4 EPS by 9c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $3.66 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Guggenheim Upgrades Editas Medicine (EDIT) to Buy
• AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
• KB Home (KBH) Tops Q3 EPS by 16c